Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 2.41B +225.6% |
| Revenue (ttm) | n/a |
| Net Income | -152.09M |
| EPS | -1.43 |
| Shares Out | 111.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,588,777 |
| Open | 22.35 |
| Previous Close | 22.48 |
| Day's Range | 21.29 - 22.39 |
| 52-Week Range | 7.63 - 24.60 |
| Beta | -0.20 |
| Analysts | Strong Buy |
| Price Target | 27.50 (+27.14%) |
| Earnings Date | Aug 6, 2026 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $27.5, which is an increase of 27.14% from the latest price.
News
Amylyx price target raised to $30 from $22 at BofA
BofA raised the firm’s price target on Amylyx (AMLX) to $30 from $22 and keeps a Buy rating on the shares. The firm adjusted targets for several stocks in its…
Amylyx price target raised to $28 from $19 at Baird
Baird raised the firm’s price target on Amylyx (AMLX) to $28 from $19 and keeps an Outperform rating on the shares. The firm updated its model ahead of LUCIDITY Phase…
Amylyx Pharmaceuticals Earnings Call Transcript: Q2 2026
Phase III LUCIDITY trial for avexitide in PBH nears top-line data, with NDA and commercial launch preparations underway for 2027. Q2 2026 ended with $250.8M in cash, supporting a runway into 2028, while pipeline programs and disease awareness efforts advance.
Amylyx Pharmaceuticals Earnings release: Q2 2026
Amylyx Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Amylyx Pharmaceuticals Quarterly report: Q2 2026
Amylyx Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Amylyx sees cash runway into 2028
Cash, cash equivalents, and short-term investments were $250.8 million at June 30, 2026, compared to $279.8 million at March 31, 2026. Based on its current operating plans, Amylyx (AMLX) expects…
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results.
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026.
Amylyx price target raised to $26 from $20 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Amylyx (AMLX) to $26 from $20 and keeps a Buy rating on the shares. The firm sees a favorable setup…
Amylyx price target raised to $24 from $21 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx (AMLX) to $24 from $21 and keeps an Outperform rating on the shares. The firm expects the company to…
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Amylyx price target raised to $40, named a Best Idea at Guggenheim
Guggenheim raised the firm’s price target on Amylyx (AMLX) to $40 from $30 and keeps a Buy rating on the shares, which are also elevated to the analyst’s “Best Idea”…
Amylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial
Amylyx (AMLX) Pharmaceuticals announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS Meeting 2026, held from June…
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026.
Amylyx Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Avexitide, a GLP-1 receptor antagonist for PBH, is in phase III with results expected in Q3. The company targets a 2027 launch, supported by strong clinical data, robust market opportunity, and a pipeline including a long-acting candidate and ALS therapy. Cash runway extends into 2028.
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026.
Amylyx Pharmaceuticals Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by stockholders. No questions were raised, and voting results will be filed with the SEC.
Amylyx announces publication of Phase 2 open-label HELIOS trial data
Amylyx (AMLX) Pharmaceuticals announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taur...
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical ...
Amylyx Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
AVEXITIDE is nearing pivotal phase III data for PBH, with strong prior efficacy and minimal expected placebo effect. Commercial plans target 160,000 U.S. patients, with a 2027 launch anticipated and cash runway into 2028. Expansion includes a long-acting version and pipeline assets for rare diseases.
Amylyx sees cash runway into 2028
Cash, cash equivalents, and short-term investments were $279.8 million at March 31, 2026, compared to $317.0 million at December 31, 2025. Based on its current operating plans, Amylyx (AMLX) expects…
Amylyx Pharmaceuticals Earnings Call Transcript: Q1 2026
Advanced pivotal LUCIDITY trial for avexitide in PBH, with top-line data expected next quarter and NDA preparations underway. Q1 operating expenses rose 16% year-over-year, with a strong cash position supporting a potential 2027 launch. Expanded access and commercial readiness efforts are progressing.
Amylyx Pharmaceuticals Earnings release: Q1 2026
Amylyx Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Amylyx Pharmaceuticals Quarterly report: Q1 2026
Amylyx Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.